Clinical Efficacy of Whole-Body Aerocryotherapy in Combination with Phototherapy in Psoriasis



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Psoriasis is often resistant to standard treatment methods, and relapses frequently occur even after a full course of phototherapy. Whole-body cryotherapy may serve as an additional method that could enhance the effectiveness of psoriasis therapy. Of particular interest is its potential effect on reducing VEGF levels and vascularization in psoriatic plaques, which could strengthen the efficacy of PUVA therapy, result in a more pronounced therapeutic response, and provide longer remission after the main treatment course. The combined use of PUVA therapy and whole-body cryotherapy (WBC) may therefore represent a promising pathogenetic approach in psoriasis treatment.

Objective. To evaluate the comparative effectiveness of combined PUVA therapy and whole-body cryotherapy in patients with psoriasis.

Materials and Methods. The study included 40 patients with moderate plaque psoriasis. Group 1 (n=20) received standard therapy according to clinical guidelines in combination with PUVA therapy. Group 2 (n=20) received standard therapy in combination with PUVA therapy and WBC. The following parameters were assessed: changes in PASI and DLQI scores, vascular endothelial growth factor (VEGF) levels, and microcirculation within psoriatic plaques using non-invasive laser Doppler flowmetry (LDF) with a Lazma MC-1 analyzer (NPP “Lazma”, Russia).

Results. After treatment, the median PASI was lower in the combined therapy group (4.0 vs. 6.0; p=0.048), with a relative PASI reduction of 75.0% vs. 62.5% (p=0.003). PASI dynamics were also significantly greater (11.75 ± 3.26 vs. 9.60 ± 3.22; p=0.042). No intergroup differences in DLQI were found after therapy (p=0.558), although the degree of improvement was more pronounced with PUVA+WBC (8.80 ± 3.27 vs. 6.30 ± 2.70; p=0.012). VEGF reduction was significantly greater in the combined therapy group (39.0 [30.25–76.75] vs. 20.0 [7.25–23.65]; p<0.001). LDF data showed decreased perfusion in both groups, with significantly lower final values in PUVA+WBC patients (9.58 ± 2.27 vs. 11.41 ± 2.83; p=0.030). The dynamics of σ were also more pronounced in the combined treatment group (1.18 vs. 0.51; p=0.023), indicating stabilization of microcirculation. Kv values did not differ significantly (p>0.3).

Conclusion. This study presents comparative results of combined PUVA therapy and WBC in patients with mild to moderate psoriasis. The addition of WBC to standard PUVA therapy enhances therapeutic effectiveness, as evidenced by a greater reduction in PASI, significant improvement in quality of life, a marked decrease in VEGF levels, and normalization of microcirculation parameters compared with PUVA monotherapy.

Full Text

Restricted Access

About the authors

Nikolay Georgievich Kochergin

I.M.Setchenov First Moscow State Medical University

Email: nkocha@yandex.ru
ORCID iD: 0000-0001-7136-4053

доктор мед. наук, профессор

Moscow, Russia

Anna A. Brezhneva

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: anna-brezhneva@mail.ru
ORCID iD: 0009-0002-2489-1269
SPIN-code: 2414-7049
Russian Federation, Moscow

Olga S. Yazkova

Central polyclinic

Email: olesha230808@mail.ru
ORCID iD: 0000-0002-9644-4778
SPIN-code: 9548-9076

MD, Cand. Sci. (Med.)

Russian Federation, Moscow

References

  1. Man AM, Orăsan MS, Hoteiuc OA, Olănescu-Vaida-Voevod MC, Mocan T. Inflammation and Psoriasis: A Comprehensive Review. Int J Mol Sci. 2023 Nov 8;24(22):16095. doi: 10.3390/ijms242216095. PMID: 38003284; PMCID: PMC10671208.
  2. Bu J, Ding R, Zhou L, Chen X, Shen E. Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review. Front Immunol. 2022 Jun 10;13:880201. doi: 10.3389/fimmu.2022.880201. PMID: 35757712; PMCID: PMC9226890.
  3. Olisova, O. Y., & Garanyan, L. G. (2017). Epidemiology, etiopathogenesis, and comorbidity in psoriasis: new facts. Russian Journal of Skin and Venereal Diseases, (4). Retrieved from https://cyberleninka.ru/article/n/epidemiologiya-etiopatogenez-i-komorbidnost-pri-psoriaze-novye-fakty
  4. Griffiths, C. E. M., Armstrong, A. W., Gudjonsson, J. E., & Barker, J. N. W. N. (2021). Psoriasis. The Lancet, 397(10281), 1301–1315. doi: 10.1016/s0140-6736(20)32549-6
  5. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205-212. doi: 10.1111/jdv.13854
  6. Kochergin, N. G., Brezhneva, A. A., Yatskova, O. S., & Fadeev, A. A. (2024). Angiogenesis in psoriasis as a therapeutic target: A literature review. Russian Journal of Skin and Venereal Diseases, 27(3), 348–359. https://doi.org/10.17816/dv627134
  7. Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020 Apr;182(4):840-848. doi: 10.1111/bjd.18245. Epub 2019 Oct 15. PMID: 31225638; PMCID: PMC7187293.
  8. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021 Apr 3;397(10281):1301-1315. doi: 10.1016/S0140-6736(20)32549-6. PMID: 33812489.
  9. Heidenreich R, Röcken M, Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol. 2009;90(3):232-248. doi: 10.1111/j.1365-2613.2009.00669.x
  10. Lee HJ, Hong YJ, Kim M. Angiogenesis in Chronic Inflammatory Skin Disorders. International Journal of Molecular Sciences. 2021; 22(21):12035. https://doi.org/10.3390/ijms222112035
  11. Mohta, Alpana; Mohta, Achala1; Ghiya, Bhikam C.. Assessing the Association between Psoriasis and Cardiovascular Ischemia: An Investigation of Vascular Endothelial Growth Factor, Cutaneous Angiogenesis, and Arterial Stiffness. Indian Dermatology Online Journal 14(5):p 653-657, Sep–Oct 2023. | doi: 10.4103/idoj.idoj_246_23
  12. Patil, Deena; Sumathy, Tharayil Kunneth; Shyamprasad, Arakali Lakshminarayana. Relevance of Serum Vascular Endothelial Growth Factor (VEGF) and Serum Interleukin-10 in the Severity of Psoriasis in South Indian Patients: A Case–Control Study. Turkish Journal of Dermatology 17(1):p 6-10, Jan–Mar 2023. | doi: 10.4103/tjd.tjd_46_22
  13. Morar II, Tabăran FA, Mocan T, et al. Immunohistochemical study of psoriatic plaques and perilesional skin in psoriasis vulgaris patients: A pilot study. Exp Ther Med. 2019;18(2):888-894. doi: 10.3892/etm.2019.7596
  14. Luengas-Martinez, A., Paus, R. and Young, H.S. (2022), A novel personalized treatment approach for psoriasis: anti-vascular endothelial growth factor-A (VEGF-A) therapy. Br J Dermatol, 186: 782-791. https://doi.org/10.1111/bjd.20940
  15. Zhou, X., Chen, Y., Cui, L. et al. Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis 13, 81 (2022). https://doi.org/10.1038/s41419-022-04523-3
  16. Luengas-Martinez A, Ismail D, Paus R, Young HS. Inhibition of vascular endothelial growth factor-A downregulates angiogenesis in psoriasis: A pilot study. Skin Health Dis. 2023;3(5):e245. Published 2023 May 15. doi: 10.1002/ski2.245
  17. Li YH, Liu JL. Psoriasis pathogenesis: What’s new in angiogenesis and angiopoietins. Indian J Dermatol Venereol Leprol. 2024;90(2):150-157. doi: 10.25259/IJDVL_622_2022
  18. Elmets CA et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019 Sep;81(3):775-804. doi: 10.1016/j.jaad.2019.04.042. Epub 2019 Jul 25. Erratum in: J Am Acad Dermatol. 2020 Mar;82(3):780. PMID: 31351884.
  19. Akman A, Dicle O, Yilmaz F, Coskun M, Yilmaz E. Discrepant levels of vascular endothelial growth factor in psoriasis patients treated with PUVA, Re-PUVA and narrow-band UVB. Photodermatol Photoimmunol Photomed. 2008 Jun;24(3):123-7. doi: 10.1111/j.1600-0781.2008.00349.x. PMID: 18477130.
  20. Shaker OG, Khairallah M, Rasheed HM, Abdel-Halim MR, Abuzeid OM, El Tawdi AM, El Hadidi HH, Ashmaui A. Antiangiogenic effect of methotrexate and PUVA on psoriasis. Cell Biochem Biophys. 2013 Nov;67(2):735-42. doi: 10.1007/s12013-013-9563-2. PMID: 23504632.
  21. Nofal A, Al-Makhzangy I, Attwa E, Nassar A, Abdalmoati A. Vascular endothelial growth factor in psoriasis: an indicator of disease severity and control. J Eur Acad Dermatol Venereol. 2009 Jul;23(7):803-6. doi: 10.1111/j.1468-3083.2009.03181.x. Epub 2009 Mar 6. PMID: 19309427.
  22. Chen, Y.; Tai, Z.; Zhu, C.; Yu, Q.; Zhu, Q.; Chen, Z. Vascular Endothelial Growth Factor A VEGFA Inhibition: An Effective Treatment Strategy for Psoriasis. Int. J. Mol. Sci. 2024, 25, 59. https://doi.org/10.3390/ijms25010059
  23. Coimbra S, Figueiredo A, Castro E, Rocha-Pereira P, Santos-Silva A. Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-α levels in patients with psoriasis before, during and after psoralen–ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol. 2010;163(6):1282-90. doi: 10.1111/j.1365-2133.2010.09992.x.
  24. Karpova, A. V., Vasenova, V. Y., & Butov, Y. S. (2010). The effect of cryotherapy in the complex treatment of psoriasis on immunological parameters and clinical outcomes. Bulletin of the Russian State Medical University, (2). Retrieved from https://cyberleninka.ru/article/n/vliyanie-krioterapii-v-kompleksnom-lechenii-psoriaza-na-immunologicheskie-pokazateli-i-klinicheskie-rezultaty
  25. Zembron-Lacny, A.; Morawin, B.; Wawrzyniak-Gramacka, E.; Gramacki, J.; Jarmuzek, P.; Kotlega, D.; Ziemann, E. Multiple Cryotherapy Attenuates Oxi-Inflammatory Response Following Skeletal Muscle Injury. Int. J. Environ. Res. Public Health 2020, 17, 7855. https://doi.org/10.3390/ijerph17217855
  26. Jurecka, A.; Woźniak, A.; Mila-Kierzenkowska, C.; Augustyńska, B.; Oleksy, Ł.; Stolarczyk, A.; Gądek, A. The Influence of Single Whole-Body Cryostimulation on Cytokine Status and Oxidative Stress Biomarkers during Exhaustive Physical Effort: A Crossover Study. Int. J. Mol. Sci. 2023, 24, 5559. https://doi.org/10.3390/ijms24065559
  27. Chun E, Joseph R, Pojednic R. Whole-Body Cryotherapy Reduces Systemic Inflammation in Healthy Adults: Pilot Cohort Study. Interact J Med Res. 2024;13:e60942. Published 2024 Nov 22. doi: 10.2196/60942

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) Eco-Vector

License URL: https://eco-vector.com/for_authors.php#07

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 86501 от 11.12.2023 г
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80653 от 15.03.2021 г
.